SEARCH

SEARCH BY CITATION

References

  • 1
    Holdaas H, Fellstrom B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003: 361: 2024.
  • 2
    Holdaas H, Fellstrom B, Cole E et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005: 5: 2929.
  • 3
    Jardine AG, Gaston RS, Fellstrom BC, Holdaas H. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet 2011: 378: 1419.
  • 4
    Abedini S, Holme I, Marz W et al. Inflammation in renal transplantation. Clin J Am Soc Nephrol 2009: 4: 1246.
  • 5
    Grebe SO, Mueller TF. Immune monitoring in organ transplantation using neopterin. Curr Drug Metab 2002: 3: 189.
  • 6
    Reynolds JJ, Brown GM. The biosynthesis of folic acid. IV. Enzymatic synthesis of dihydrofolic acid from guanine and ribose compounds. J Biol Chem 1964: 239: 317.
  • 7
    Gostner JM, Becker K, Fuchs D, Sucher R. Redox regulation of the immune response. Redox Rep 2013: 18: 88.
  • 8
    Huber C, Batchelor JR, Fuchs D et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984: 160: 310.
  • 9
    Hoffmann G, Wirleitner B, Fuchs D. Potential role of immune system activation-associated production of neopterin derivatives in humans. Inflamm Res 2003: 52: 313.
  • 10
    De Rosa S, Cirillo P, Pacileo M et al. Neopterin: from forgotten biomarker to leading actor in cardiovascular pathophysiology. Curr Vasc Pharmacol 2011: 9: 188.
  • 11
    Mangge H, Almer G, Truschnig-Wilders M, Schmidt A, Gasser R, Fuchs D. Inflammation, adiponectin, obesity and cardiovascular risk. Curr Med Chem 2010: 17: 4511.
  • 12
    Holdaas H, Fellstrom B, Holme I et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. J Cardiovasc Risk 2001: 8: 63.
  • 13
    Aulitzky WE, Tilg H, Niederwieser D et al. Comparison of serum neopterin levels and urinary neopterin excretion in renal allograft recipients. Clin Nephrol 1988: 29: 248.
  • 14
    Svensson M, Dahle DO, Mjoen G et al. Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study. Nephrol Dial Transplant 2012: 27: 2571.
  • 15
    Yadav AK, Sharma V, Jha V. Association between serum neopterin and inflammatory activation in chronic kidney disease. Mediators Inflamm 2012: 2012: 476979.
  • 16
    Dahle DO, Mjoen G, Oqvist B et al. Inflammation-associated graft loss in renal transplant recipients. Nephrol Dial Transplant 2011: 26: 3756.
  • 17
    Troppmair J, Nachbaur K, Herold M et al. In-vitro and in-vivo studies on the induction of neopterin biosynthesis by cytokines, alloantigens and lipopolysaccharide (LPS). Clin Exp Immunol 1988: 74: 392.
  • 18
    Ray KK, Morrow DA, Sabatine MS et al. Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation 2007: 115: 3071.
  • 19
    Grammer TB, Fuchs D, Boehm BO, Winkelmann BR, Maerz W. Neopterin as a predictor of total and cardiovascular mortality in individuals undergoing angiography in the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem 2009: 55: 1135.
  • 20
    Fuchs D, Avanzas P, Arroyo-Espliguero R, Jenny M, Consuegra-Sanchez L, Kaski JC. The role of neopterin in atherogenesis and cardiovascular risk assessment. Curr Med Chem 2009: 16: 4644.
  • 21
    Vengen IT, Dale AC, Wiseth R, Midthjell K, Videm V. Neopterin predicts the risk for fatal ischemic heart disease in type 2 diabetes mellitus: long-term follow-up of the HUNT 1 study. Atherosclerosis 2009: 207: 239.
  • 22
    Avci E, Coskun S, Cakir E, Kurt Y, Ozgur Akgul E, Bilgi C. Relations between concentrations of asymmetric dimethylarginine and neopterin as potential risk factors for cardiovascular diseases in haemodialysis-treated patients. Ren Fail 2008: 30: 784.
  • 23
    Estevez-Loureiro R, Recio-Mayoral A, Sieira-Rodriguez-Moret JA, Trallero-Araguas E, Kaski JC. Neopterin levels and left ventricular dysfunction in patients with chronic stable angina pectoris. Atherosclerosis 2009: 207: 514.
  • 24
    Sulo G, Vollset SE, Nygard O et al. Neopterin and kynurenine-tryptophan ratio as predictors of coronary events in older adults, the Hordaland Health Study. Int J Cardiol 2013: 168: 1435.
  • 25
    Stenvinkel P, Barany P. Dialysis in 2011: can cardiovascular risk in dialysis patients be decreased? Nat Rev Nephrol 2011: 8: 72.
  • 26
    Nafar M, Sahraei Z, Salamzadeh J, Samavat S, Vaziri ND. Oxidative stress in kidney transplantation: causes, consequences, and potential treatment. Iran J Kidney Dis 2011: 5: 357.
  • 27
    Turkmen K, Tonbul HZ, Toker A et al. The relationship between oxidative stress, inflammation, and atherosclerosis in renal transplant and end-stage renal disease patients. Ren Fail 2012: 34: 1229.
  • 28
    Heeger PS, Dinavahi R. Transplant immunology for non-immunologist. Mt Sinai J Med 2012: 79: 376.
  • 29
    Schennach H, Murr C, Gachter E, Mayersbach P, Schonitzer D, Fuchs D. Factors influencing serum neopterin concentrations in a population of blood donors. Clin Chem 2002: 48: 643.
  • 30
    Wolf J, Musch E, Neuss H, Klehr U. Neopterin in the serum and urine in the differential diagnosis of disorders of kidney function following kidney transplantation. Klin Wochenschr 1987: 65: 225.
  • 31
    Kameoka H, Takahara S, Takano Y et al. Serum and urinary neopterin as markers in renal transplant patients. Int Urol Nephrol 1994: 26: 107.
  • 32
    Margreiter R, Fuchs D, Hausen A et al. Neopterin as a new biochemical marker for diagnosis of allograft rejection. Experience based upon evaluation of 100 consecutive cases. Transplantation 1983: 36: 650.
  • 33
    Reibnegger G, Aichberger C, Fuchs D et al. Posttransplant neopterin excretion in renal allograft recipients–a reliable diagnostic aid for acute rejection and a predictive marker of long-term graft survival. Transplantation 1991: 52: 58.
  • 34
    Chin GK, Adams CL, Carey BS, Shaw S, Tse WY, Kaminski ER. The value of serum neopterin, interferon-gamma levels and interleukin-12B polymorphisms in predicting acute renal allograft rejection. Clin Exp Immunol 2008: 152: 239.
  • 35
    Schafer AJ, Daniel V, Dreikorn K, Opelz G. Assessment of plasma neopterin in clinical kidney transplantation. Transplantation 1986: 41: 454.
  • 36
    Lee PH, Huang MT, Chung YC et al. Monitoring of serum neopterin in renal transplant recipients. J Formos Med Assoc 1992: 91: 1209.
  • 37
    Grebe SO, Kuhlmann U, Fogl D, Luyckx VA, Mueller TF. Macrophage activation is associated with poorer long-term outcomes in renal transplant patients. Clin Transplant 2011: 25: 744.
  • 38
    Carey BS, Jain R, Adams CL et al. Serum neopterin as an indicator of increased risk of renal allograft rejection. Transpl Immunol 2013: 28: 81.
  • 39
    Weimer R, Susal C, Yildiz S et al. sCD30 and neopterin as risk factors of chronic renal transplant rejection: impact of cyclosporine A, tacrolimus, and mycophenolate mofetil. Transplant Proc 2005: 37: 1776.
  • 40
    Weimer R, Susal C, Yildiz S et al. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens. Am J Transplant 1865: 2006: 6.
  • 41
    Bakr A, Rageh I, El-Azouny M, Deyab S, Lotfy H. Serum neopterin levels in children with primary nephrotic syndrome. Acta Paediatr 2006: 95: 854.
  • 42
    Weiss MF, Rodby RA, Justice AC, Hricik DE. Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy. Collaborative Study Group. Kidney Int 1998: 54: 193.
  • 43
    Baris N, Erdogan M, Sezer E et al. Alterations in L-arginine and inflammatory markers in type 2 diabetic patients with and without microalbuminuria. Acta Diabetol 2009: 46: 309.
  • 44
    Roodnat JI, Mulder PG, Rischen-Vos J et al. Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 2001: 72: 438.
  • 45
    Fernandez-Fresnedo G, Plaza JJ, Sanchez-Plumed J, Sanz-Guajardo A, Palomar-Fontanet R, Arias M. Proteinuria: a new marker of long-term graft and patient survival in kidney transplantation. Nephrol Dial Transplant 2004: 19(Suppl. 3): iii47.
  • 46
    Frick B, Schroecksnadel K, Neurauter G, Leblhuber F, Fuchs D. Increasing production of homocysteine and neopterin and degradation of tryptophan with older age. Clin Biochem 2004: 37: 684.
  • 47
    Spencer ME, Jain A, Matteini A et al. Serum levels of the immune activation marker neopterin change with age and gender and are modified by race, BMI, and percentage of body fat. J Gerontol A Biol Sci Med Sci 2010: 65: 858.